Allergy training and immunotherapy in Latin America: results of a regional overview

被引:12
作者
Baena-Cagnani, Carlos E. [1 ]
Larenas Linnemann, Desiree [2 ]
Gomez, Maximiliano [3 ]
Gonzalez Diaz, Sandra [4 ]
Sole, Dirceu [5 ]
Sanchez Borges, Mario [6 ]
Bousquet, Jean [7 ]
Carlos Sisul, Juan [8 ]
Walter Canonica, Giorgio [9 ]
Gereda, Jose [10 ]
Passalacqua, Giovanni [9 ]
机构
[1] Catholic Univ, Fdn LIBRA, Res Ctr Resp Med CIMER, Cordoba, Argentina
[2] Hosp Med Sur, Mexico City, DF, Mexico
[3] Hosp San Bernardo, Salta, Argentina
[4] Univ Nuevo Leon, Ctr Reg Alergia, Monterrey, Mexico
[5] Escola Paulista Med, BR-04023 Sao Paulo, Brazil
[6] Ctr Med Docente Trinidad, Caracas, Venezuela
[7] Hop Arnaud Villeneuve, Univ Hosp, Montpellier, France
[8] ARIA Paraguay SLAAI, Asuncion, Paraguay
[9] Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy
[10] Cln Ricardo Palma, Lima, Peru
关键词
ASTHMA; PREVALENCE; RHINITIS; DISEASES; RECOMMENDATIONS; STATEMENT; SYMPTOMS; TRIALS;
D O I
10.1016/j.anai.2013.08.011
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: One main practice gap in allergology that has been detected in several regions of the world is the application of specific immunotherapy (SIT). The prescription and practice of SIT should characterize allergologic specialists, but there are regional discrepancies in such practice. A detailed knowledge of the regulatory and legislation aspects and drawbacks would help improve and harmonize SIT practice. Objective: To describe in Latin America the level of allergy training and the characteristics of the use of SIT, including the medical and legal aspects. Methods: Three sources were used: a 24-item questionnaire sent to 22 allergologic leaders in 11 Latin American countries, 2 face-to-face meetings, and information from health authorities involved in the approval of medical substances. Results: In 56% of countries, the specialty of allergology is a third-level care specialty and/or a subspecialty. Two countries have a special training program for pediatric allergists. Passing a board examination is mandatory in 3 countries, and recertification every 2 to 5 years occurs without examination. Sublingual and subcutaneous SITs are available in all Latin American countries. No legislation restricts SIT prescription and it can be performed by nonspecialists in 7 of 11 countries. In 90% of countries, allergists use allergen extracts from the United States (subcutaneous immunotherapy) and Europe (sublingual and subcutaneous immunotherapies), and 50% also manufacture extracts locally. Only 1 country has legal requirements for the quality of raw materials. Conclusion: The present analysis helps to identify gaps in the field of allergologic training and SIT in Latin America, many of them amendable. (C) 2013 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:415 / +
页数:6
相关论文
共 37 条
[1]   Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? [J].
Allam, J. -P. ;
Stojanovski, G. ;
Friedrichs, N. ;
Peng, W. ;
Bieber, T. ;
Wenzel, J. ;
Novak, N. .
ALLERGY, 2008, 63 (06) :720-727
[2]   Standards for practical allergen-specific immunotherapy [J].
Alvarez-Cuesta, E. ;
Bousquet, J. ;
Canonica, G. W. ;
Durham, S. R. ;
Mailing, H. -J. ;
Valovirta, E. .
ALLERGY, 2006, 61 :1-20
[3]   Trends in the prevalence of asthma and other allergic diseases in schoolchildren from Cuernavaca, Mexico [J].
Barraza-Villarreal, Albino ;
Hernandez-Cadena, Leticia ;
Moreno-Macias, Hortensia ;
Ramirez-Aguilar, Matiana ;
Romieu, Isabelle .
ALLERGY AND ASTHMA PROCEEDINGS, 2007, 28 (03) :368-374
[4]   How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2LEN statement [J].
Bousquet, J. ;
Schuenemann, H. J. ;
Bousquet, P. J. ;
Bachert, C. ;
Canonica, G. W. ;
Casale, T. B. ;
Demoly, P. ;
Durham, S. ;
Carlsen, K-H ;
Malling, H-J ;
Passalacqua, G. ;
Simons, F. E. R. ;
Anto, J. ;
Baena-Cagnani, C. E. ;
Bergmann, K-C ;
Bieber, T. ;
Briggs, A. H. ;
Brozek, J. ;
Calderon, M. A. ;
Dahl, R. ;
Devillier, P. ;
van Wijk, R. Gerth ;
Howarth, P. ;
Larenas, D. ;
Papadopoulos, N. G. ;
Schmid-Grendelmeier, P. ;
Zuberbier, T. .
ALLERGY, 2011, 66 (06) :765-774
[5]   Allergen immunotherapy: Therapeutic vaccines for allergic diseases - A WHO position paper [J].
Bousquet, J ;
Lockey, R ;
Malling, HJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (04) :558-562
[6]  
Cagnani Carlos E Baena, 2009, Rev Alerg Mex, V56, P56
[7]  
Cagnani Carlos E Baena, 2008, Rev Alerg Mex, V55, P33
[8]  
Calderon MA, 2012, CLIN TRANSL ALLERGY, V2, P8
[9]   Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce [J].
Canonica, G. W. ;
Baena-Cagnani, C. E. ;
Bousquet, J. ;
Bousquet, P. J. ;
Lockey, R. F. ;
Malling, H. -J. ;
Passalacqua, G. ;
Potter, P. ;
Valovirta, E. .
ALLERGY, 2007, 62 (03) :317-324
[10]   100 Years of Immunotherapy: The Monaco Charter [J].
Canonica, G. Walter ;
Baena-Cagnani, Carlos E. ;
Compalati, Enrico ;
Bohle, Barbara ;
Bonini, Sergio ;
Bousquet, Jean ;
Cox, Linda ;
Fink-Wagner, Antje H. ;
Gonzalez Diaz, Sandra ;
Jacobsen, Lars ;
Passalacqua, Giovanni ;
Pawankar, Ruby ;
Vieths, Stefan ;
Yusuf, Osman ;
Zuberbier, Torsten .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2013, 160 (04) :346-349